Know Labs, Inc.

Know Labs, Inc. focuses on the development and commercialization of proprietary technologies in the United States. Its technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a molecular signature. The company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into various wearable, mobile, or bench-top form factors. Its first application of Bio-RFID technology is a product marketed as a glucose monitor that provide the user with real time information on their blood glucose levels. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in May 2018. Know Labs, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Know Labs, Inc. trades as KNW on AMEX. The company is classified in Technology / Hardware, Equipment & Parts and reports in USD.

The current profile places the business in Hardware, Equipment & Parts. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$24.35B of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Know Labs, Inc. can be compared against peers such as GSE Systems, Inc., Intelligent Protection Management Corp., Minim, Inc., Moatable, Inc., Myseum Inc., NextTrip, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $16.05M, beta of 1.76, and return on equity of -25.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

KNW currently shows total debt of $342.79M and beta of 1.76. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 8-K (2026-06-04 00:00:00), 10-Q (2026-05-13 00:00:00), 8-K (2026-05-01 00:00:00), 10-K/A (2026-04-27 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.knowlabs.co

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.